Clinical trial
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
NCT07895017 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
- Lead sponsor
- University of Virginia
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- August 31, 2029
- Enrollment
- 26 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 1 arm.
-
Avatrombopag Arm
All participants are anticipated to receive a 39 day supply of oral Avatrombopag.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Number of participants with platelets ≥50K
Number of participants with platelets ≥50K for 2 consecutive laboratory checks within 1 week, and one of those measures occurring at day 28. The last platelet transfusion must be \>2 days from the first day of platelets ≥50K.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Avatrombopag
- US 7638536; expires July 28, 2027; assignee Astellas Pharma (Japan)
Lead sponsor's other trials
University of Virginia, most recent start first.
+671 more trials See the organization page
Similar trials
Same condition (Thrombocytopenia) and phase, most recent start first.
+114 more trials See the condition page